EPO orphan meeting
Executive Summary
FDA Blood and Blood Products Advisory Committee meeting scheduled for June 29 has been put on hold, according to FDA. The committee is to consider whether Amgen's Epogen and Chugai-Upjohn's Marogen are different products for the purpose of determining the extent of Epogen orphan exclusivity.